Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
STAGING AND TREATMENT OF KAPOSI'S SARCOMA IN PATIENTS WITH AIDS
AIDS. The Epidemic of Kaposi's Sarcoma and Opportunistic Infections. Friedman-Kien AE, Laubenstein LJ, eds. New York, Masson, p. 51-5, 1984.. Unique Identifier : AIDSLINE ICDB/85610689 Laubenstein L; Div. of Hematology, Dept. of Medicine, New York Univ. Medical; Center, New York, NY 10016
Abstract:
Kaposi's sarcoma (KS) is classified as Stage I when cutaneous and locally indolent, Stage II when cutaneous and locally aggressive, Stage III when mucocutaneous or when lymph node involvement is generalized, and Stage IV when visceral. The disease is subtyped as A when systemic signs or symptoms are absent and as B when they are present. Complete staging requires skin photography and biopsy, abdominal computerized tomography, endoscopy, colonoscopy, bronchoscopy (when the chest radiograph is abnormal), liver scan, and bone scan (when the alkaline phosphatase is abnormal). Estimated probability of survival at 36 mo has been reported to be 100% for Stage I, 60% for Stages IIIA and IVA, and 20% for Stages IIIB and IVB. In a nonrandomized clinical comparison of etoposide and combination therapy with adriamycin, bleomycin and vinblastine (ABV), complete responses were observed in 37.5% and 18.5% of etoposide and ABV patients (pts), respectively; partial responses in 40.6% and 62.9%; and no responses in 16.6% and 18.5%. Opportunistic infections have been more frequent with the ABV. Treatment of 5 cases with vinblastine alone resulted in partial response in 3, minimal response in 1, and no response in 1. The author concludes that these trials represent a promising beginning in the treatment of KS itself, but that treatment of immune dysfunction may be more important for pt survival. (7 Refs)
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Antineoplastic Agents, Combined/*THERAPEUTIC USE Bleomycins/ADMINISTRATION & DOSAGE Doxorubicin/ADMINISTRATION & DOSAGE Etoposide/ADMINISTRATION & DOSAGE Human Infection/COMPLICATIONS Neoplasm Staging/*METHODS Prognosis Sarcoma, Kaposi's/COMPLICATIONS/DRUG THERAPY/*PATHOLOGY Skin Neoplasms/COMPLICATIONS/DRUG THERAPY/*PATHOLOGY Vinblastine/ADMINISTRATION & DOSAGE MEETING PAPER
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
